BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
The delisting is a result of the company's non-compliance with Nasdaq Listing Rule 5550(b)(1), pertaining to its minimum shareholder equity requirement.
BrainStorm has already secured approval for its common stock to be quoted on the OTCQB Venture Market, a U.S. trading platform operated by OTC Markets Group. The company anticipates its shares will begin trading on the OTCQB under the same symbol, BCLI, beginning at the open of trading on July 18, 2025, or as soon as possible thereafter.
Chaim Lebovits, CEO of BrainStorm Cell Therapeutics, stated, 'While this delisting from Nasdaq is a challenging outcome, we want to assure our shareholders and the patient community that it does not alter our core mission or our unwavering commitment to advancing NurOwn for ALS patients. Our pre-arranged transition to OTCQB ensures continuous trading for our shares and allows us to focus entirely on NurOwn's development. We remain fully dedicated to our ongoing scientific and clinical programs, including preparations for our pivotal Phase 3b trial under the Special Protocol Assessment (SPA) agreement with the FDA.'
The company confirms that the delisting does not impact its business operations, its ongoing research and development efforts, or its commitment to its shareholders. BrainStorm will continue to provide updates on its progress and financial status in compliance with applicable SEC regulations.
About NurOwn® The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.
NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the 'Floor Effect' – a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.
Notice Regarding Forward-Looking Statements This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTS
Investors:Michael Wood Phone: +1 646-597-6983 mwood@lifesciadvisors.com
Media:Uri Yablonka, Chief Business Officer Phone: +1 917-284-2911 uri@brainstorm-cell.com
Logo – https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-nasdaq-delisting-and-transition-to-otcqb-302508133.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
an hour ago
- Malaysian Reserve
OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology
BELLEVUE, Wash. and SEOUL, South Korea, July 24, 2025 /PRNewswire/ — OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced it has signed a term sheet ('Term Sheet') with Woori IO Co., Ltd. ('WORIO'), a South Korean medical device company developing next-generation noninvasive glucose monitoring technology. The agreement sets forth certain key terms for a strategic acquisition of WORIO by OSR Holdings' Korean affiliate, OSR Holdings Co., Ltd. ('OSRK'). Under the proposed structure, WORIO will become a wholly owned subsidiary of OSRK. Shareholders of WORIO will receive newly issued shares of OSRK through the share exchange and may be eligible to convert them into OSRH common stock traded on NASDAQ, subject to certain conditions including '$10 per OSRH share' WORIO shareholders may convert their OSRK shares into OSRH shares at a fixed exchange ratio of 1 OSRK share = 12.96 OSRH shares, provided that OSRH's stock price reaches $10.00 at least once within three years following the signing of the Term Sheet. If this condition is not met, the parties have agreed to renegotiate in good faith. The agreement includes a 6-month exclusivity period, during which OSRK will conduct confirmatory legal and financial due diligence with a target to complete this transaction within this exclusivity proprietary platform uses near-infrared spectroscopy (NIRS) to measure glucose without needles, sensors, or skin penetration — representing a truly noninvasive alternative to today's continuous glucose monitors (CGMs). Its solution aims to eliminate the burden of pain and daily finger pricks for millions of people with diabetes. According to recent global market research, the blood glucose monitoring devices market is expected to exceed $40 billion by 2030, growing at a CAGR of 8–10%, driven by rising diabetes prevalence and the convergence of medical technology with consumer electronics. Demand for noninvasive and wearable monitoring systems is expected to be a major growth driver. Dexcom, one of the market leaders in minimally invasive CGM which is the current standard of care has more than $32 billion in market capitalization (as of July 11), underscoring the significant commercial potential of advanced glucose monitoring solutions. Noninvasive alternatives hold tremendous promise and are poised to become an integral part of diabetes management in the future. WORIO has completed a proof-of-concept study with the Korea University Hospital (Guro) to validate the accuracy and effectiveness of its prototype devices and the data measured by them, based on which the company plans to enter a larger confirmatory trial to be registered with the Ministry of Food and Drug Safety (MFDS) of Korea for medical device approval pathway. WORIO's noninvasive technology is well positioned to be integrated into wearable glucose monitoring devices such as smart watches — WORIO has been selected by Samsung Electronics' innovative startup program ('C-Lab Outside') in Q1 2025.'We believe this initial milestone with Woori IO aligns strongly with our mission to accelerate breakthrough healthcare innovations with global impact,' said Peter Hwang, CEO of OSRH. 'Woori IO's breakthrough noninvasive glucose monitoring platform, coupled with its high-profile partnership with global companies, puts OSRH in a position to become a first mover in this fast-growing global market.'Following the signing of this Term Sheet, both parties will proceed with due diligence and aim to execute definitive agreements within the 6 months exclusivity period. About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting-edge research and development. For more information, visit About Woori IO Co., Ltd. Woori IO is a medical device company based in Jeonju, South Korea, focused on the development of noninvasive biosensing solutions. Its proprietary NIRS-based glucose monitoring system enables accurate, pain-free, and user-friendly diabetes management, with strong potential for wearable integration. For more information, visit Contact:Investor RelationsOSR Holdings, IR@ Website:
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Fla.'s Housing Market: Inventory Up, Prices Continue to Moderate in June
ORLANDO, Fla., July 23, 2025 /PRNewswire/ — In June, closed sales of single-family existing homes statewide rose 2.8% compared to a year ago, according to Florida Realtors®' latest housing data. Continuing trends seen over the past few months, Florida's housing market also reported higher inventory levels (active listings), and easing median sales prices in June and second quarter (2Q) 2025 year over year. 'As Florida's housing market continues to transition toward balance, opportunities are emerging on both sides of the transaction,' said 2025 Florida Realtors® President Tim Weisheyer, broker-owner, Dream Builders Realty and dbrCommercial Real Estate Services in Central Florida. 'Motivated sellers who understand today's market dynamics are attracting qualified buyers and enjoying the benefits of accumulated equity in their homes, and with June marking a positive year-over-year increase in single-family sales, the momentum is real. 'Whether buying or selling, there is no question Floridians benefit from having a Realtor® by their side – someone with true insight, real data and experience to guide them through the complexities of this evolving market.' Last month, closed sales of existing single-family homes statewide totaled 23,827, up 2.8% year-over-year, while existing condo-townhouse sales totaled 7,809, down 6.4% over June 2024, according to data from Florida Realtors Research Department in partnership with local Realtor boards/associations. For 2Q 2025, statewide existing single-family home sales totaled 72,155, down 2.6% from 2Q 2024, while statewide existing condo-townhouse sales totaled 24,864, down 14.2% year-over-year. Closed sales may occur from 30- to 90-plus days after sales contracts are written. Looking at the for-sales picture, Florida Realtors Chief Economist Dr. Brad O'Connor said June's 2.8% increase in closed sales of single-family homes year-over-year represented the first gain in that metric since January. He noted, 'This rebound helped to temper what would have been an otherwise very sluggish second quarter for closings. As a result, second quarter single-family sales were only down 2.6%. And, condo and townhouse sales were down by 20% relative to a year ago in May, so June's decline of only 6.4% was far less severe by comparison.' The statewide median sales price for single-family existing homes in June was $412,000, down 3.5% compared to June 2024, while the statewide median price for condo-townhouse units was $300,000, down 7.7% from a year ago. For 2Q 2025, Florida's single-family median sales price was $414,900, down 3.1% compared to the same quarter a year ago; the condo-townhouse median for 2Q was $310,000, down 6.1% year-over-year. The median is the midpoint; half the homes sold for more, half for less. Turning to listings, O'Connor said, 'There were 2.7% fewer single-family homes listed for sale this June than in the same month last year. That's the second straight month with a decline after we saw a fair amount of growth in new listings over the first four months of the year. Single-family new listings for the second quarter overall were down by 0.7%, and this trend will likely continue through the summer months. 'New listings of condos and townhouses were down 7.5% year over year in June, and by 6.2% for the second quarter overall. This cooling of new listings has led to a slowdown in inventory growth in recent months, despite sales being well below where they were last year.' On the supply side of the market, single-family existing homes were at a 5.6-months' supply in June and 2Q 2025, while condo-townhouse properties were at a 10-months' supply for both timeframes. While inventory growth has slowed, the level of months' supply in both property categories favors buyers at the negotiating table, O'Connor said, particularly when it comes to the 10-months' supply level statewide for condos and townhouse units. To see the full statewide housing activity reports, go to the Florida Realtors Newsroom and look under Latest Releases or download the June 2025 and 2Q 2025 data report PDFs under Market Data. Florida Realtors® is The Voice for Real Estate® in Florida. It provides programs, services, continuing education, research and legislative representation to 238,000 members in 50 boards/associations. Florida Realtors® Newsroom website is available at
The Star
11 hours ago
- The Star
Asian markets extend gains on US trade deal hopes
HONG KONG: Asian markets extended the week's gains Thursday (July 24) on optimism other countries will follow up Japan's US trade deal with ones of their own, with speculation building that the European Union is on course. Investors have been on a roll in recent weeks on bets that governments will eventually hammer out pacts with Donald Trump ahead of the US president's Aug 1 deadline. The mood has been upbeat since news that Japan had reached a deal to lower sweeping tariffs from 25 per cent to 15 per cent, including those on the country's crucial car sector. The breakthrough fanned hopes that others were in the pipeline. However, there is talk that the European Union is edging towards an agreement. Reports say Brussels could get something similar to Japan, with tariffs cut to 15 per cent -- from the threatened 30 per cent. The Financial Times said the two would waive tariffs on some products, including aircraft, spirits and medical devices. That came after US Treasury Secretary Scott Bessent said negotiations were making progress, with talks planned later in the day between the bloc's top trade negotiator and his American counterpart. Analysts said a deal with Washington's biggest trading entity would provide a massive boost to equities However, failure to reach a deal, triggering Trump's 30 per cent levies on Aug 1, could cause havoc on markets, analysts warned. France has been loudest in insisting Brussels must show it is willing to deploy its trade weapon, known as the anti-coercion instrument -- allowing officials to take measures such as import and export restrictions on goods and services. Neil Wilson at Saxo Markets warned that would end up "effectively killing trade between the two... the nuclear option is on the table it seems, but for the moment expectation seems to be veering towards a deal". After another record day for the S&P 500 and Nasdaq on Wall Street, Asia picked up the baton and ran. Tokyo piled on two per cent, having jumped more than three per cent Wednesday on the trade deal, while Hong Kong continued its standout year with another advance. Shanghai, Seoul, Singapore, Wellington, Taipei and Manila also rose. Traders are also keeping an eye on developments in Tokyo after Japanese Prime Minister Shigeru Ishiba denied discussing his resignation with party elders on Wednesday, as speculation about his future intensified following a weekend election debacle. Despite the saga, the yen extended its gains, briefly hitting 145.86 per dollar as the trade deal allows investors to turn their attention to the Bank of Japan's policy meeting next week hoping for guidance on its next interest rate hike. The unit had been sitting around 147.90 before the deal. Bank officials have held off rocking the boat on the issue amid tariff uncertainty, but observers say the agreement can allow them to reconsider lifting in October. - AFP
